Alkem Imperia Online Quiz - June'2018
-
Dabiclot reduces the risk of first stroke or systemic embolism over warfarin by:
-
20%
-
25%
-
30%
-
35%
-
Alkem Imperia
Quiz Preview
- 2.
What is MUPS technology?
-
Multiple Particulate technology
-
Multi Unit Particulate System technology
-
Multi Para System technology
-
None of the above
Correct Answer
A. Multi Unit Particulate System technology -
- 3.
What are the competitors of Dabiclot?
-
Pradaxa
-
Dabistar
-
Dabigat
-
All options are true
Correct Answer
A. All options are true -
- 4.
What is the quantity of Business Desk Lamp received per ME?
-
20
-
40
-
30
-
10
Correct Answer
A. 10 -
- 5.
Which competitor brand will you focus on for conversion to Muzika?
-
Isolazine
-
Isoflav
-
Isodac
-
Isoniazid
Correct Answer
A. Isolazine -
- 6.
RELYABLE trial was an extension of RELY trail for how many years:
-
4 years
-
6 years
-
2.3 years
-
1 year
Correct Answer
A. 2.3 years -
- 7.
Dose of Dabiclot in patients with creatinine clearance 15-30ml/min will be:
-
150mg BID
-
110mg BID
-
75mg BID
-
Not recommended
Correct Answer
A. 75mg BID -
- 8.
Dabiclot 110mg reduces risk of intracranial bleeding over Warfarin by what percent:
-
69%
-
65%
-
60%
-
55%
Correct Answer
A. 69% -
- 9.
Ezuric/Muzika is being promoted to how many doctors?
-
5
-
10
-
15
-
20
Correct Answer
A. 20 -
- 10.
What is HPMC?
-
Hydroxy Pentyl Mono Cellulose
-
Hydroxy Propyl Methyl Cellulose
-
Hydro Propane Methane Cellulose
-
None of the above
Correct Answer
A. Hydroxy Propyl Methyl Cellulose -
- 11.
What is the quantity of JAPI reprints received per ME?
-
20
-
40
-
30
-
60
Correct Answer
A. 60 -
- 12.
Ezuric is indicated in which class of patients:
-
NYHA Class I
-
NYHA Class II
-
NYHA Class III
-
NYHA Class II – IV
Correct Answer
A. NYHA Class II – IV -
- 13.
The special input (Business desk Lamp) will be given on priority to which set of drs:
-
RM/DSM adopted drs
-
20 drs selected for effort driven conversion for Dabiclot
-
10 drs selected for Ezuric/Muzika
-
Any dr out of 60
Correct Answer
A. RM/DSM adopted drs -
- 14.
Why will a dr prefer Dabiclot over other brands of Dabigatran
-
Innovative manufacturing process to overcome technical challenges
-
HPMC capsule shell
-
Bioequivalence study compared with US Innovator
-
All of the above
Correct Answer
A. All of the above -
- 15.
Muzika is indicated in which class of patients:
-
NYHA Class I
-
NYHA Class II
-
NYHA Class III
-
NYHA Class III – IV
Correct Answer
A. NYHA Class III – IV -
- 16.
Clot Case Series Issue 6 talks about which of the following topics:
-
Use of Dabigatran in patient not responding to Warfarin
-
Use of Dabigatran in a non anti coagulated patient determined on basis of CHADSVASc Score
-
Use of Dabigatran in patient with AF on antiplatelet therapy
-
None of the above
Correct Answer
A. Use of Dabigatran in a non anti coagulated patient determined on basis of CHADSVASc Score -
- 17.
In case of the Drs being targeted for Ezuric and Muzika, which brand will be promoted first?
-
Dabiclot
-
Ezuric
-
Muzika
-
Any of the above
Correct Answer
A. Dabiclot -
- 18.
Chemist availability for Ezuric/Muzika is to be done at how many retailers?
-
10
-
20
-
30
-
40
Correct Answer
A. 30 -
- 19.
Dabiclot brand reminder input for the month of May was:
-
Dabiclot paper weight
-
Dabiclot Chit pad
-
Dabiclot Rx pad
-
None of the above
Correct Answer
A. Dabiclot Chit pad -
- 20.
Which competitor brand(s) will you focus on for conversion to Ezuric?
-
Isodac
-
Eptus
-
Planep
-
Both b & c are true
Correct Answer
A. Both b & c are true -
Quiz Review Timeline (Updated): Mar 20, 2022 +
Our quizzes are rigorously reviewed, monitored and continuously updated by our expert board to maintain accuracy, relevance, and timeliness.
-
Current Version
-
Mar 20, 2022Quiz Edited by
ProProfs Editorial Team -
Jun 20, 2018Quiz Created by
Kumar
Back to top